Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Charles River Laboratories International's annualized net income for the quarter that ended in Dec. 2023 was $748 Mil. Charles River Laboratories International's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $-414 Mil. Therefore, Charles River Laboratories International's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was Negative Tangible Equity%.
The historical rank and industry rank for Charles River Laboratories International's Return-on-Tangible-Equity or its related term are showing as below:
CRL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 50.88 Med: 105.85 Max: 160.82
Current: Negative Tangible Equity
During the past 13 years, Charles River Laboratories International's highest Return-on-Tangible-Equity was 160.82%. The lowest was 50.88%. And the median was 105.85%.
CRL's Return-on-Tangible-Equity is ranked better than 99.51% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.89
vs CRL: Negative Tangible Equity
Charles River Laboratories International Return-on-Tangible-Equity Historical Data
The historical data trend for Charles River Laboratories International's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Charles River Laboratories International Annual Data
For the Diagnostics & Research subindustry, Charles River Laboratories International's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Charles River Laboratories International Return-on-Tangible-Equity Distribution
For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Charles River Laboratories International's Return-on-Tangible-Equity falls into.
Charles River Laboratories International Return-on-Tangible-Equity Calculation
Charles River Laboratories International's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2023) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
Charles River Laboratories International (NYSE:CRL) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Charles River Laboratories International Return-on-Tangible-Equity Related Terms
Thank you for viewing the detailed overview of Charles River Laboratories International's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Charles River Laboratories International (Charles River Laboratories International) Business Description
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRL has been successfully added to your 